Markopol MD

French Radiation Oncologist, Star Wars Fanatic, Motorcycle Enthusiast

[Piet Ost @piet_ost]

🔬 PEACE 2 phase III: Adding pelvic RT to prostate RT + 3y ADT in very high-risk localized prostate cancer did NOT improve bPFS, MFS, CSS or OS. Borderline cPFS signal (HR 0.81, p=0.09). No added AEs. @PBlanchard_MD #ESTRO2026. @VedangMurthy what now?

[Pierre Blanchard, MD @PBlanchardMD]

🚨improved OS with ADT+enza in high risk BCR (biochemical recurrent) #prostatecancer

New standard of care but important to reconcile the data with the results of PRESTO AFT19 (apalutamide) & integration in current landscape (PSMA, MDT).

#ESMO25

[Diego A. Díaz-García @diegoadiazg]

🫁 ALEX: final OS. @TonyMok9

Survival benefit with first-line alectinib vs crizotinib in advanced ALK+ NSCLC (mOS 81.1 vs 54.2 mo).
Benefit observed regardless of CNS metastases status; safety consistent with prior data.

#ESMO25 #CánCare #NSCLC #ALK #lcsm

[Hidehito HORINOUCHI @HHorinouchi]

🆙#ESMO25🇩🇪
🔥#LCSM Proffered paper, non-mets, SCLC
☑️SKYSCRAPER-03: Phase III, open-label, randomised study of atezolizumab + tiragolumab vs durvalumab in stage III NSCLC after platinum-based cCRT
☑️OS 19.4m vs. 16.6m, HR 0.96 (95%CI 0.75-1.23)
🎙️Dr. Rafal Dziadziuszko
@OncoAlert @myESMO @Larvol

[Oscar Tahuahua @OscarTahuahua]

#ESMO25 KEYNOTE-905/EV-303
Perioperative pembro + Enfortumab vedotin vs surgery alone in cisplatin ineligible MIBC

The combo achieved major gains ↑EFS HR 0.40, ↑OS HR 0.50, ↑pCR 57% vs 9% (P<.001)

Practice changing & the new SoC in this setting 🌟
@OncoAlert @myESMO

[Oscar Tahuahua @OscarTahuahua]

#ESMO25
FLAURA2: Final OS analysis confirmed Osi + CTx ↑ OS vs Osi mono (HR 0.77; p=0.02) in 1L EGFRm NSCLC.

Benefit was consistent across poor-prognosis subgroups (CNS mets, L858R, plasma EGFRm+, TP53 altered), reinforcing combo as the 1L SoC
@OncoAlert @myESMO

[Jordi Remon @JordiRemon]

ALEX trial 1st L alectinib (vs crizo) not ⬆️OS but trial not powered for OS. The best drug first? living w/o disease PD and good control of risk of brain PD count most!!Today lorlatinib is one SoC, futute SoC in 1st line Neladalkib (NVL655), ALKZAR trial vs alectinib?. #ESMO25

[Giuseppe Banna @gbanna74]

A real BRIDGE very clever study to fill the gap between resectable and borderline resectable #nsclc with early MDT reassessment and high resection rate and pCR. Excellent presentation as usual by ⁦Martin Reck
⁦@OncoAlert⁩ ⁦@ONCOassist⁩

[Hidehito HORINOUCHI @HHorinouchi]

🆙#ESMO25🇩🇪
🔥#LCSM Proffered paper, mets
☑️ALEX: Final OS of ALEX study of alectinib vs crizotinib in ALK-positive NSCLC
☑️Alectinib/Crizotinib mOS 81.1m/54.2m
🎙️ @TonyMok9
@OncoAlert @myESMO @Larvol

[Hidehito HORINOUCHI @HHorinouchi]

🔥BREAKING‼️ @NEJM 🆙
✅Survival with Osimertinib plus Chemo in EGFR-Mutated Advanced NSCLC
🎯mOS 47.5m vs. 37.6m, HR 0.77 (95%CI, 0.61 to 0.96)
🎙️ Dr. Pasi A. Jänne
#WCLC25 #ESMO25 #LCMS
@IASLC @myESMO @OncoAlert @Larvol
https://t.co/Lp3AiRvwiS

[Diego A. Díaz-García @diegoadiazg]

🫁 MDT-BRIDGE @MartinReck2 @myESMO

In stage IIB–select IIIB NSCLC, close MDT reassessment during neoadjuvant durvalumab + chemo enabled local treatment in 95% of pts.
Resection rate 85.7% (94% R0), pCR 27.6%.
Outcomes consistent with AEGEAN, even including borderline resectable cases.

#CánCare #NSCLC #lcsm #ESMO25

[Shankar Siva @_ShankarSiva]

📣 #ESMO25: NORTHSTAR RCT @YasirElaminMD; n=120 EGFR-mut #lungcancer osimertinib +/- LCT (68% #radiotherapy)
⬆️ 12-month PFS rate: 72% vs 54%
⬆️ PFS (25.3 vs 17.5 mo; HR 0.66; P=0.025)
😳 really not “oligo” population!
✅Grade ≥3 AEs: 29% (LCT arm) vs 22% (control) #radonc

[Clive Peedell @cpeedell]

Practice changing results from PROTECT trial. Patients with cribriform positive disease do better with radiotherapy & hormones rather than surgery or active surveillance #radonc #pcsm https://t.co/PvDPHU5tuL

[Pierre Blanchard, MD @PBlanchardMD]

KN905

Very impressive results with neoadjuvant EV-P in cisplatin-ineligible muscle invasive #bladdercancer presented by C Vulsteke at #ESMO25

✅Improved PFS & OS
✅High path CR rates (57%)
✅No delay in surgery
✅Expected toxicity in this frail population

New SOC

[Pierre Blanchard, MD @PBlanchardMD]

Key question is whether this would allow bladder preservation protocols and not cystectomy.

What is the point of removing 57% of intact bladders? Could we do less to improve patients QoL?

#radonc

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

Tarlatamab incorporated upfront with chemo-immunotherapy breaks all the known stats in first-line SCLC. No new data safety concerns. Awaiting data from randomized ph3 trial, but likely to be the next SoC. #ESMO25 #SCLC @SclcSMASHERS

[Drew Moghanaki @DrewMoghanaki]

The long-awaited results of NORTHSTAR are finally reported at #ESMO25. @fifimcdrmh

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

Median overall survival for newly diagnosed metastasic ALK+ lung cancer patient treated with alectinib is …. 🥁

81 months

#ESMO25 #LCSM @TonyMok9 ALEX trial

[Emre Yekedüz @yekeduz_emre]

3068O – CheckMate 274 (5-yr update) #ESMO25
💪 Adjuvant nivolumab continues to show durable benefit vs placebo in high-risk MIUC.
🕒 DFS: 21.9 vs 11.0 mo (HR 0.74)
🧬 ctDNA(+): HR 0.35 → clear benefit
🧫 PD-L1 ≥1%: DFS 55.5 vs 8.4 mo (HR 0.58)
OS trend favors NIVO (HR 0.83)

@OncoAlert @myESMO @DrYukselUrun #Cancer #Oncology @DrChoueiri

[Pierre Blanchard, MD @PBlanchardMD]

STOPCAP at #ESMO26

Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS.

Restricted to <5 bone or low volume mets on conventional imaging.

No interaction with other patient/tumor characteristics.